ORLY Stock Recent News

O'Reilly Automotive (ORLY) came out with quarterly earnings of $9.96 per share, beating the Zacks Consensus Estimate of $9.71 per share. This compares to earnings of $9.26 per share a year ago.

Aftermarket automotive parts specialist O'Reilly Automotive (ORLY 1.05%) reported mixed fourth-quarter and full-year 2024 earnings on Wednesday, Feb. 5. While Q4 revenue surpassed analysts' consensus estimates, reaching $4.1 billion compared to the expected $4.05 billion, the earnings per share (EPS) of $9.50 underperformed relative to the $9.75 forecast.

SPRINGFIELD, Mo., Feb. 05, 2025 (GLOBE NEWSWIRE) -- O'Reilly Automotive, Inc. (the “Company” or “O'Reilly”) ( Nasdaq: ORLY), a leading retailer in the automotive aftermarket industry, today announced record revenue for its fourth quarter and full-year ended December 31, 2024. The results represent 32 consecutive years of comparable store sales growth and record revenue and operating income for O'Reilly since becoming a public company in April of 1993.

Tariffs and currency headwinds are impacting costs and currency, making US retail and service-related stocks a nice hedge. Key stocks to consider include home improvement, grocery, automotive retail, and waste management. Hedging against tariff uncertainty should become a theme in years to come.

Besides Wall Street's top -and-bottom-line estimates for O'Reilly Automotive (ORLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

O'Reilly Automotive (ORLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

O'Reilly Automotive (ORLY) possesses solid growth attributes, which could help it handily outperform the market.

Texas Pacific Land and Taiwan Semiconductor Manufacturing were top contributors for both the quarter and the year, showcasing strong earnings growth and strategic market positioning. Despite Texas Pacific Land's strong performance, we sold our positions due to overvaluation driven by index additions, with plans to re-invest post-market correction. Edwards Lifesciences' EARLY TAVR trial results highlight significant potential for expanding aortic stenosis treatment, positioning the company for double-digit earnings growth in the coming years.

In the last 10 years, the S&P 500 has done historically well for investors, producing an annualized total return of 13.2%. That's well ahead of the 10% yearly average over the very long term.

While the auto parts industry grapples with significant challenges in the DIY segment, ORLY and AZO are poised to capitalize on evolving market dynamics.